4.84 0.00 (0.00%)
After hours: 5:16PM EST
|Bid||4.20 x 4000|
|Ask||5.35 x 800|
|Day's Range||4.7157 - 4.9300|
|52 Week Range||4.1000 - 12.3550|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.40|
The announcement of what appeared to be positive mid-stage trial data seemed to do little to assuage investors in light of the fact that the drug remains on hold due to cardiovascular concerns.
Zafgen, Inc. (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced positive data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of ZGN-1061 up to 1.8 mg. The clinical trial met all of its primary objectives at the 1.8 mg dose, which included glycemic control, or change in A1C, and safety and tolerability. The 12-week data demonstrated that treatment with the 1.8 mg dose of ZGN-1061 produced substantially more improvement in A1C than the 0.9 mg dose.
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
Zamansky LLC announces that it is investigating Zafgen, Inc. (ZFGN) (“Zafgen” or the “Company”) for potential breaches of fiduciary duties by its officers and board of directors. If you are a shareholder of Zafgen who still holds your shares, please contact our firm for information. It has recently emerged from public filings that Zafgen has received a letter from the U.S. Food and Drug Administration (“FDA”) citing possible cardiovascular safety risks associated with the clinical trial of a new type 2 diabetes drug ZGN-1061 as the reason for placing a clinical hold on the trial.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zafgen, Inc. (''Zafgen'' or the ''Company'') (NASDAQ: ZFGN). ...
NEW YORK , Nov. 28, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zafgen, Inc. ("Zafgen" or the "Company") (NASDAQ: ZFGN). Such investors are ...
Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.
Earlier today, shares of Zafgen Inc. (ZFGN) plunged 41% on news that the Food and Drug Administration placed a clinical hold on the company's Investigative New Drug Application (IND) for ZGN-1061, an early-stage candidate drug for the treatment of type 2 diabetes. Zafgen is a clinical-stage biopharmaceutical company specializing in the study of MetAP2 inhibitors in common and rare metabolic disorders. It is currently pursuing research into type 2 diabetes, Prader-Willi syndrome and hepatic diseases.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Zafgen was one of the big decliners in the biotech arena after the FDA put a clinical hold on its Investigational New Drug Application. Shares of Edge Therapeutics were also in the red after announcing a definitive merger agreement with PDS Biotechnology Corporation. Zafgen, Inc. shares sank on Monday nearly 40.5% at the close.
Beleaguered Boston biotech Zafgen's stock price was cut nearly in half Monday after it announced that the FDA has halted its plans to begin testing a type 2 diabetes drug.
Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks. Zafgen said it planned to assess the options put forward by the FDA in a letter last week and request a meeting with the agency to discuss the next steps with the clinical trial.
Zafgen Inc. said Monday the Food and Drug Administration ha placed a clinical hold on its investigational new drug application (IND) for the biopharmaceutical company's first U.S. clinical trial of its type 2 diabetes treatment, citing the possibility of cardiovascular safety risk. The stock was halted for news until 7:30 a.m. Eastern. The FDA outlined multiple potential paths for moving forward, including nonclinical and clinical options to address the concerns. Zafgen said it plans to assess the options and request a Type A meeting with the FDA. Zafgen said that with the delay of additional clinical development for ZGN-1061, the company now expects its cash runway to extend through 2020. The stock has soared 97% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 3.3% and the S&P 500 has lost 1.5%.